⌘K
Loading ticker…
As of 2026-08-21, Skye Bioscience, Inc. Common Stock (SKYE) has a 3-month relative strength percentile of 4 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 26. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 20.5%, relative volume 0.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
SKYE is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -54.3% / -66.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
SKYE is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $345K notional.
Held by 3 ETFs · $630K across latest filings · largest weight 0.02% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $345K | — |
| VXFVanguard Extended Market ETF | 0.00% | $114K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SKYE Jan avg: 24.07% median: 24.07% win: 100% σ: 15.06% n: 2 2024-04-12 → 2026-07-31 | SKYE Feb avg: -18.73% median: -18.73% win: 0% σ: 10.63% n: 2 2024-04-12 → 2026-07-31 | SKYE Mar avg: -30.85% median: -30.85% win: 0% σ: 18.89% n: 2 2024-04-12 → 2026-07-31 | SKYE Apr avg: 27.33% median: 37.11% win: 100% σ: 22.23% n: 3 2024-04-12 → 2026-07-31 | SKYE May avg: -10.38% median: -10.21% win: 0% σ: 1.31% n: 3 2024-04-12 → 2026-07-31 | SKYE Jun avg: 23.17% median: -10.59% win: 33% σ: 76.84% n: 3 2024-04-12 → 2026-07-31 | SKYE Jul avg: -22.68% median: -18.00% win: 0% σ: 11.19% n: 3 2024-04-12 → 2026-07-31 | SKYE Aug avg: 8.88% median: 8.88% win: 50% σ: 15.34% n: 2 2024-04-12 → 2026-07-31 (current) | SKYE Sep avg: -12.27% median: -12.27% win: 50% σ: 34.73% n: 2 2024-04-12 → 2026-07-31 | SKYE Oct avg: -13.27% median: -13.27% win: 50% σ: 66.88% n: 2 2024-04-12 → 2026-07-31 | SKYE Nov avg: -14.90% median: -14.90% win: 0% σ: 0.83% n: 2 2024-04-12 → 2026-07-31 | SKYE Dec avg: -39.87% median: -39.87% win: 0% σ: 4.10% n: 2 2024-04-12 → 2026-07-31 |